Navigation Links
Claimsnet.com Reports Second Quarter 2009 Results
Date:7/30/2009

DALLAS, July 30 /PRNewswire-FirstCall/ -- Claimsnet.com inc. (OTC Bulletin Board: CLAI), a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2009, which ended June 30, 2009.

For the quarter ended June 30, 2009, Claimsnet reported revenues of $563,000, a 6% increase compared to the $529,000 reported for the second quarter of 2008. Revenues for the six months ended June 30, 2009 were $1,082,000, a 6% increase compared to the $1,018,000 reported for the six months of 2008.

Cost of revenues for the second quarter of 2009 was $419,000 compared to $422,000 for the second quarter of 2008, a 1% decrease. Cost of revenues for the six months of 2009 was $832,000 compared to $810,000 for the six months of 2008, a 3% increase. Selling, general and administrative expenses of $221,000 were reported for the second quarter of 2009 compared to $281,000 reported for the second quarter of 2008, a 21% decrease. Selling, general and administrative expenses of $472,000 were reported for the six months of 2009 compared to $487,000 reported for the six months of 2008, a 3% decrease.

Claimsnet reported a gross profit of $144,000 for the second quarter of 2009, compared with a gross profit of $107,000 for the second quarter of 2008, a 35% increase. Claimsnet reported a gross profit of $250,000 for the six months of 2009, compared with a gross profit of $208,000 for the six months of 2008, a 20% increase.

The loss from operations for the second quarter of 2009 was $(77,000) compared to $(174,000) reported for the second quarter of 2008, a decrease of 56%. The loss from operations for the six months of 2009 was $(222,000) compared to $(279,000) reported for the six months of 2008, a decrease of 20%. The net loss for the second quarter of 2009 was $(87,000), or $(
'/>"/>

SOURCE Claimsnet.com
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Claimsnet.com Reports First Quarter 2009 Results
2. Claimsnet.com Reports Fiscal Year 2008 Results
3. Claimsnet.com Reports Third Quarter 2008 Results
4. Claimsnet.com Reports First Quarter 2008 Results
5. Claimsnet.com Reports Fiscal Year 2007 Results
6. Palomar Medical Reports Financial Results for Second Quarter 2009
7. Medifast Reports Record Second Quarter 2009 Financial Results
8. CryoLife Reports Record Quarterly Revenues of $28.2 Million
9. Gentiva Reports Second Quarter 2009 Results
10. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
11. Encision Reports Profitable First Fiscal Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 1AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 2AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 3Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 1Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 2Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 3Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 4Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 1Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 2Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 3